Date: April 18, 2026 | Executive Order: “Accelerating Medical Treatments for Serious Mental Illness”
On April 18, 2026, President Donald Trump signed an executive order directing the FDA to fast-track reviews of certain psychedelics — with specific focus on ibogaine — for treating serious mental illnesses such as PTSD, depression, anxiety, and addiction, particularly among veterans.
Key provisions include:
- Commissioner’s National Priority Vouchers for breakthrough therapies to speed up FDA review
- Establishment of a Right to Try pathway with FDA/DEA support for eligible patients
- $50 million in federal research funding allocated to states advancing psychedelic programs
- Emphasis on ibogaine compounds for treatment-resistant conditions
The signing ceremony in the Oval Office included Joe Rogan, RFK Jr., and veterans’ advocates.
New York Times & related outlets — Coverage highlighting loosening restrictions on psychedelic drugs.
Coverage was consistent across major outlets (Fox News, Reuters, NPR, PBS/AP, NYT, CNN, The Guardian, etc.), emphasizing the veterans’ mental health focus, policy details on ibogaine, and potential impacts on research and treatment access.
Official Source: White House Executive Order
For full articles or more details, visit the linked official sources or major news outlets.
